Issue

Vol. 63 No. 11: Issue 11

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Potential biomarkers for the diagnosis of respiratory tract infection and lungs cancer

https://doi.org/10.14715/cmb/2017.63.11.9
Khushbukhat Khan
Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan
Muhammad Adeel Aslam
Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan
Fatima Tuz Zahra
Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan
Hamid Basheer
Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan
Muhammad Bilal
Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan
Aleena Sumrin
Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan

Corresponding Author(s) : Aleena Sumrin

aleena.camb@pu.edu.pk

Cellular and Molecular Biology, Vol. 63 No. 11: Issue 11

Abstract

Major hurdle faced by many physicians in treating various respiratory tract infections and lung carcinomas is their late or mis-diagnosis. In most respiratory tract infections the manner of infection is not completely understood. Similarly, various lung carcinomas are diagnosed at advance stages at which not only the treatment possibilities are narrowed but the chances of survival are also reduced. So, for the sake of better treatment, the quick and improved diagnostic strategies are suggested. Protein biomarkers fully fit the description in this regard as they have shown great potential in specific diagnosis of many respiratory diseases and also have shown capability in timely pin pointing different stages of lung carcinomas. Many serum biomarkers are presently being used for diagnosis but the efficiency for diagnosis of these biomarkers is lower when used alone. So, physicians are suggested to use the combination of different biomarkers. Moreover, genetic biomarkers are also currently studied to indicate the exact stage of disease, the possible damage occurred, the severity of disease and also for the analysis of the possible body response to the therapeutics.

Keywords

Respiratory tract infections Lungs carcinomas Serum biomarkers Protein biomarkers Genomic biomarkers.
Khan, K., Aslam, M. A., Zahra, F. T., Basheer, H., Bilal, M., & Sumrin, A. (2017). Potential biomarkers for the diagnosis of respiratory tract infection and lungs cancer. Cellular and Molecular Biology, 63(11), 46–52. https://doi.org/10.14715/cmb/2017.63.11.9
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Colburn W, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Biomarkers Definitions Working Group. Clinical Pharmacol & Therapeutics. 2001;69:89-95.
  2. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. The case for early detection. Nature Reviews Cancer. 2003;3(4):243-52.
  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
  4. Sung H-J, Cho J-Y. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB reports. 2008;41(9):615-25.
  5. Bharti A, Ma PC, Salgia R. Biomarker discovery in lung cancer”promises and challenges of clinical proteomics. Mass spectrometry reviews. 2007;26(3):451-66.
  6. Arya SK, Bhansali S. Lung cancer and its early detection using biomarker-based biosensors. Chemical reviews. 2011;111(11):6783-809.
  7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: a cancer journal for clinicians. 2007;57(1):43-66.
  8. Bai T, Vonk J, Postma D, Boezen H. Severe exacerbations predict excess lung function decline in asthma. European Respiratory Journal. 2007;30(3):452-6.
  9. Wedzicha JA, Hurst JR. Chronic obstructive pulmonary disease exacerbation and risk of pulmonary embolism. Thorax. 2007;62(2):103-4.
  10. Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E, et al. COPD exacerbations: the importance of a standard definition. Respiratory medicine. 2004;98(2):99-107.
  11. Blasi F, Stolz D, Piffer F. Biomarkers in lower respiratory tract infections. Pulmonary pharmacology & therapeutics. 2010;23(6):501-7.
  12. Casado B, Pannell LK, Iadarola P, Baraniuk JN. Identification of human nasal mucous proteins using proteomics. Proteomics. 2005;5(11):2949-59.
  13. Dalton WS, Friend SH. Cancer biomarkers”an invitation to the table. Science. 2006;312(5777):1165-8.
  14. Tothill IE, editor Biosensors for cancer markers diagnosis. Seminars in cell & developmental biology; 2009: Elsevier.
  15. Ocak S, Chaurand P, Massion PP. Mass Spectrometry–based Proteomic Profiling of Lung Cancer. Proceedings of the American Thoracic Society. 2009;6(2):159-70.
  16. Rasooly A, Jacobson J. Development of biosensors for cancer clinical testing. Biosensors and Bioelectronics. 2006;21(10):1851-8.
  17. Ho J-aA, Chang H-C, Shih N-Y, Wu L-C, Chang Y-F, Chen C-C, et al. Diagnostic detection of human lung cancer-associated antigen using a gold nanoparticle-based electrochemical immunosensor. Analytical chemistry. 2010;82(14):5944-50.
  18. Li Z, Wang Y, Wang J, Tang Z, Pounds JG, Lin Y. Rapid and sensitive detection of protein biomarker using a portable fluorescence biosensor based on quantum dots and a lateral flow test strip. Analytical chemistry. 2010;82(16):7008-14.
  19. Salgia R, Harpole D, Herndon 2nd J, Pisick E, Elias A, Skarin A. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer research. 2000;21(2B):1241-6.
  20. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer. 2006;107(12):2842-9.
  21. Molina R, AUGE JM, Filella X, VIí‘OLAS N, ALICARTE J, DOMINGO JM, et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer research. 2005;25(3A):1773-8.
  22. Zhong Z, Shan J, Zhang Z, Qing Y, Wang D. The Signal"Enhanced Label"Free Immunosensor Based on Assembly of Prussian Blue"SiO2 Nanocomposite for Amperometric Measurement of Neuron"Specific Enolase. Electroanalysis. 2010;22(21):2569-75.
  23. Schneider J, Philipp M, Velcovsky H-G, Morr H, Katz N. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer research. 2002;23(2A):885-93.
  24. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clinical biochemistry. 2004;37(7):529-40.
  25. Petrović M, Bukumirić Z, Zdravković V, Mitrović S, Atkinson HD, Jurišić V. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer. Medical oncology. 2014;31(2):1-7.
  26. Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clinical Cancer Research. 2011;17(8):2395-9.
  27. Okutani D. [The role of long pentraxin 3, a new inflammatory mediator in inflammatory responses]. Nihon Rinsho Men'eki Gakkai kaishi= Japanese journal of clinical immunology. 2006;29(3):107-13.
  28. Nikliński J, Furman M, Palynyczko Z, Laudański J, Bułatowicz J. Carcinoembryonic antigen, neuron-specific enolase and creatine kinase-BB as tumor markers for carcinoma of the lung. Neoplasma. 1990;38(6):645-51.
  29. Ye F, Shi M, Huang Y, Zhao S. Noncompetitive immunoassay for carcinoembryonic antigen in human serum by microchip electrophoresis for cancer diagnosis. Clinica Chimica Acta. 2010;411(15):1058-62.
  30. Heo SH, Lee SJ, Ryoo HM, Park JY, Cho JY. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC"MS/MS. Proteomics. 2007;7(23):4292-302.
  31. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. The Journal of clinical investigation. 2006;116(1):271-84.
  32. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, et al. A multiparametric serum kallikrein panel for diagnosis of non–small cell lung carcinoma. Clinical Cancer Research. 2008;14(5):1355-62.
  33. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine. 2009;361(10):958-67.
  34. Riely GJ, Marks J, Pao W. KRAS mutations in non–small cell lung cancer. Proceedings of the American Thoracic Society. 2009;6(2):201-5.
  35. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Reviews Cancer. 2008;8(1):11-23.
  36. Galasso M, Elena Sana M, Volinia S. Non-coding RNAs: a key to future personalized molecular therapy. Genome Med. 2010;2(2):12.
  37. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung cancer. 2010;67(2):170-6.
  38. Moreira A, Sapru A, Rimensberger PC. What's new about circulating biomarkers in pediatric acute lung disease. Intensive care medicine. 2016;42(5):803-5.
  39. Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. European Respiratory Journal. 2007;30(3):556-73.
  40. Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. European journal of clinical investigation. 2007;37(2):145-52.
  41. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. CHEST Journal. 1989;96(1):68-73.
  42. Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine. 1998;158(5):1680-4.
  43. Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, Makita K, et al. Receptor for advanced glycation end"products is a marker of type I lung alveolar cells. Genes to Cells. 2004;9(2):165-74.
  44. Dahlin K, Mager EM, Allen L, Tigue Z, Goodglick L, Wadehra M, et al. Identification of genes differentially expressed in rat alveolar type I cells. American journal of respiratory cell and molecular biology. 2004;31(3):309-16.
  45. Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. American journal of respiratory and critical care medicine. 2004;170(7):766-72.
  46. Bernard A, Marchandise F, Depelchin S, Lauwerys R, Sibille Y. Clara cell protein in serum and bronchoalveolar lavage. European Respiratory Journal. 1992;5(10):1231-8.
  47. Broers J, Jensen S, Travis W, Pass H, Whitsett J, Singh G, et al. Expression of surfactant associated protein-A and Clara cell 10 kilodalton mRNA in neoplastic and non-neoplastic human lung tissue as detected by in situ hybridization. Laboratory investigation; a journal of technical methods and pathology. 1992;66(3):337-46.
  48. Peri A, Cordella-Miele E, Miele L, Mukherjee AB. Tissue-specific expression of the gene coding for human Clara cell 10-kD protein, a phospholipase A2-inhibitory protein. Journal of Clinical Investigation. 1993;92(5):2099.
  49. Hermans C, Bernard A. Lung epithelium–specific proteins: characteristics and potential applications as markers. American journal of respiratory and critical care medicine. 1999;159(2):646-78.
  50. Joyce C, Fiscus R, Wang X, Dries D, Morris R, Prinz R. Calcitonin gene-related peptide levels are elevated in patients with sepsis. Surgery. 1990;108(6):1097-101.
  51. Müller B, Becker KL, Schächinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Critical care medicine. 2000;28(4):977-83.
  52. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock. 2007;28(2):219-26.
  53. Kohno N, Inoue Y, Hamada H, Fujioka S, Fujino S, Yokoyama A, et al. Difference in sero"diagnostic values among KL"6"associated mucins classified as cluster 9. International Journal of Cancer. 1994;57(S8):81-3.
  54. Kuroki Y, Tsutahara S, Shijubo N, Takahashi H, Shiratori M, Hattori A, et al. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. American Review of Respiratory Disease. 1993;147(3):723-9.
  55. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. Journal of Biological Chemistry. 1992;267(21):14987-97.
  56. Brett J, Schmidt AM, Du Yan S, Zou YS, Weidman E, Pinsky D, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. The American journal of pathology. 1993;143(6):1699.
  57. Hanford LE, Fattman CL, Shaefer L, Enghild JJ, Valnickova Z, Oury TD. Regulation of receptor for advanced glycation end products during bleomycin-induced lung injury. American journal of respiratory cell and molecular biology. 2003;29(3 Suppl):S77.
  58. Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, Fattman CL, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. The American journal of pathology. 2008;172(3):583-91.
  59. FEHRENBACH H, KASPER M, TSCHERNIG T, SHEARMAN MS, SCHUH D, MíœLLER M. RECEPTOR FORADVANCED GLYCATION ENDPRODUCTS (RAGE) EXIllBITS IDGHLY DIFFERENTIAL CELLULAR AND SUBCELLULAR LOCALISATION IN RAT AND HUMAN LUNG. Cellular and molecular biology. 1998;44(7):1147-57.
  60. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. Journal of Clinical Investigation. 1987;79(1):117.
  61. Hamilton K, Sims P. Changes in cytosolic Ca2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. Journal of Clinical Investigation. 1987;79(2):600.
  62. Rubin DB, Wiener-Kronish JP, Murray J, Green D, Turner J, Luce J, et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. Journal of Clinical Investigation. 1990;86(2):474.
  63. Ware LB, Conner ER, Matthay MA. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Critical care medicine. 2001;29(12):2325-31.
  64. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2003;285(1):L20-L8.
  65. MOUSSA OM, ERAKY I, EL-FAR MA, OSMAN HG, GHONEIM MA. Rapid diagnosis of genitourinary tuberculosis by polymerase chain reaction and non-radioactive DNA hybridization. The Journal of urology. 2000;164(2):584-8.
  66. Umansky SR, Tomei LD. Transrenal DNA testing: progress and perspectives. Expert review of molecular diagnostics. 2006;6(2):153-63.
  67. Cannas A, Goletti D, Girardi E, Chiacchio T, Calvo L, Cuzzi G, et al. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. The international journal of tuberculosis and lung disease. 2008;12(2):146-51.
  68. Fortun J, Martí­n-Dávila P, Gomez-Mampaso E, González-Garcí­a A, Barbolla I, Gómez-Garcí­a I, et al. Extra-pulmonary tuberculosis: differential aspects and role of 16S-rRNA in urine. The International Journal of Tuberculosis and Lung Disease. 2014;18(4):478-85.
  69. Kashino S, Pollock N, Napolitano D, Rodrigues Jr V, Campos"Neto A. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clinical & Experimental Immunology. 2008;153(1):56-62.
  70. Napolitano DR, Pollock N, Kashino SS, Rodrigues V, Campos-Neto A. Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis. Clinical and Vaccine Immunology. 2008;15(4):638-43.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 925 Download : 405

Most read articles by the same author(s)